Press Release – New York, NY – March 27, 2026 – Sichenzia Ross Ference Carmel LLP announced that it represented Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a biotechnology company pioneering the development of targeted genetic medicines, in its recent $6 million underwritten public offering.
Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for the offering.
The SRFC team was led by partner Marcelle Balcombe, with associate Rohini Sud.